Moderna, Inc. shares have been in strong demand lately. The technical chart pattern looks positive which may give rise to new gains. Investors have an opportunity to buy the stock and target the $ 110.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
For the past twelve months, EPS forecast has been revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 47.93 USD
Stock prices approach a strong long-term resistance in weekly data at USD 94.85.
Technically, the stock approaches a strong medium-term resistance at USD 97.95.
Low profitability weakens the company.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The company's "enterprise value to sales" ratio is among the highest in the world.
ę MarketScreener.com 2020
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.